Antimicrobial Utilization and Stewardship: Human Medicine Perspectives



J Conly MD CCFP FRCPC FACP Professor of Medicine, Microbiology, Immunology & Infectious Diseases, University of Calgary Medical Director, Antimicrobial Stewardship Alberta Health Services - Calgary and Area

Panacea to Preservation



Source: Google Images

Disclosures

- Clinical reviewer and co-investigator: CADTH (*C. difficile* and MRSA projects)
- Grants: AI-HS, PHAC, Alberta Health, AHS, Exciton, CIHR
- Speaker or Meeting Participant (last 3 years): Pfizer (new antibacterials), bioMerieux (healthcare infections), Sanofi (*C. difficile* burden of illness), Merck (monoclonal Abs)
 Member: WHO AGISAR, GIPC Network

Objectives

- Outline the frequency and impact of antibiotic use
- Review the general background on antibiotic utilization and stewardship
- Describe the evidence base to support stewardship as a means to improve patient safety and quality of care
- Provide the Canadian context for utilization and stewardship

Antimicrobial Use

Therapeutic

- Life threatening situations
- Potentially life threatening
- Prophylaxis
 - Non-life threatening easier to alter physician prescribing behaviour
 - Accounts for up to 30% of antibiotic use

Other

Anti-inflammatory, prokinetic, fatigue of chronic lyme


Frequency of Use of Antimicrobials

- Antimicrobials are among the most commonly used class of drugs in Canadian hospitals
- Pharmacy expenditures represent significant proportion of an institution's total budget
- 55.7% of patients discharged from 323 hospitals in US in 2010 received antibiotics during their hospitalization
- Recent 2015 point prevalence survey Calgary hospitals 30% of patients on antimicrobials

Fridkin et al .Vital Signs: Improving antibiotic use among hospitalized patients. MMWR March 7, 2014 / 63(09);194-200 Nault V et al. Can J Infect Dis Med Microbiol 2008;19(3):237-242 Sabuda D, Rajapaske N, et al AMMI-CACMID Meeting 2016

5 Principles of Antibiotic Resistance

- Given sufficient time and drug use, antibiotic resistance will emerge – resistance has arisen to every antibiotic.
- 2. Resistance is progressive evolving from low levels through intermediate to high levels.
- 3. Organisms resistant to one drug are likely to become resistant to others.
- 4. Once resistance appears it is likely to decline slowly if at all.
- 5. The use of antibiotics by one person affects others in the immediate and extended environments.




methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci (VRE), and fluoroquinolone-resistant Pseudomonas aeruginosa (FQRP). These data were collected from hospital intensive care units that participate in the

National Nosocomial Infections Surveillance System, a component of the CDC (US)

Antibiotic resistant organisms are increasing. New antibiotic drug development is rapidly decreasing.¹

A perfect storm for an infectious disease catastrophe.

Chart 2: Antibacterial Agents Approved, 1983-2004



Source: Spellberg et al., *Clinical Infectious Diseases*, May 1, 2004 (modified)

Common Measures of Antimicrobial Utilization

- 1. DDD/1000 pt days
 - WHO standard; no patient level data; easy to calculate; facilitates intercountry comparisons
 - Reference DDDs may not = given dose; not for pediatrics
- 2. DOT/1000 pt days
 - Not affected by changes in WHO reference DDDs; useful for pediatrics; incorporates LOS
 - No dosage measure; requires patient level data; undercalls renal dosing
- 3. LOT/1000 pt days
 - Useful for units; requires patient level data
- Others: COT/LOT ratios; % receiving/admissions; kg used; PDDs

Antimicrobial Stewardship - Definition

"The optimal selection, dosage, and duration of antimicrobial treatment that results in the best clinical outcome for the treatment or prevention of infection, with minimal toxicity to the patient and minimal impact on subsequent resistance."

Gerding DN. Joint Commission J Qual Improv 2001:27:403-4.

Antimicrobial Stewardship - Definition

- In Canada antimicrobial stewardship is considered to be the responsible planning and management of resources in order to prevent and moderate the development of antimicrobial resistance
- May consider from multiple perspectives clinical, public health, systems, governance
 human and animal settings

Public Health Agency of Canada, Centre for Communicable Disease and Infection Control Stewardship Task Group Report 2016

Antimicrobial Stewardship Programs

Quality improvement and patient safety
 Improve quality of medical care
 Reduce adverse events and allergies

Collateral damage reduction

 Prevention of resistance by selection for drugresistant organisms [ESBLs, MRSA, VRE]
 C. difficile: AAD: unwanted colonization with

C. difficile; AAD; unwanted colonization with MDROs)

Paterson DL Clin Infect Dis 2004;38(Suppl4):S341-S34

Cost containment

Reduction in antimicrobial costs

Clinical and economic burden of antibiotic resistance

Maragakis LL et al. Expert Rev Anti Infect Ther 2008;6:751-763

Collateral Damage: Association of Antibiotics with CDAD in Quebec


Table 3: Incidence of hospital-acquired CDAD per 1000 patient-days of use of various classes of antibiotics among all inpatients at the Centre hospitalier universitaire de Sherbrooke

	Period; incidence per 1000 patient-days of antibiotic use*						
Antibiotic class	1999–2000	2001–2002	2003				
Narrow-spectrum penicillins	1.4 (28/19908)	1.2 (25/20597)	4.9 (53/10751)				
β-lactam/β-lactamase inhibitors	1.0 (7/7267)	1.3 (17/13419)	5.0 (46/9194)				
Cephalosporins							
First-generation	2.3 (30/12779)	2.6 (35/13633)	8.8 (74/8412)				
Second-generation	3.9 (55/13984)	2.9 (36/12224)	16.3 (92/5639)				
Third-generation	2.7 (18/6786)	4.6 (34/7390)	19.5 (72/3687)				
Carbapenems	2.7 (7/2553)	6.7 (15/2248)	7.4 (9/1209)				
Aminoglycosides	2.4 (21/8673)	2.2 (18/8230)	6.5 (28/4283)				
Quinolones	1.6 (48/29693)	1.2 (36/29375)	9.9 (161/16293)				
Clindamycin	4.9 (19/3861)	3.1 (11/3508)	11.7 (22/1880)				
Macrolides	1.9 (5/2625)	4.4 (12/2715)	20.0 (33/1649)				
Metronidazole	2.0 (20/10092)	1.8 (19/10696)	5.0 (39/7745)				
Vancomycin	2.5 (9/3658)	2.4 (10/4137)	5.2 (20/3853)				
Cotrimoxazole	0.2 (8/51706)	0.2 (13/54077)	0.5 (11/20287)				

*Calculated from numbers in parentheses: the numerator represents the number of patients with hospital-acquired CDAD who received a given class of antibiotic during the 2 months before diagnosis, and the denominator represents the total number of patient-days that this class of antibiotic was used among all inpatients.

Pepin J et al. CMAJ 2004;171:466-472

Failure of Infection Control Measures -Reduction in CDAD with Targeted Antibiotic Consumption Intervention



Valiquette L et al. Clin Infect Dis 2007;45 (Suppl 2):S112-S121

Antimicrobial Stewardship Policies

Persuasive

- Education for prescribers
 - Conferences
- Peer Review
 - Utilization review with feedback
- Tailoring or de-escalation of therapy
- Academic detailing
 - Face to face presentations
- Therapeutic guidelines
 - National, regional, local
- Sequential antimicrobial therapy (IV to oral conversion)
- Computer assisted decision support

Rotstein C et al. Can J Infect Dis1998;9:7C-16C

Antimicrobial Stewardship Policies

Restrictive

- Cascade susceptibility reporting
- Controlled formulary
- Automatic stop orders
 - IV vs. oral
- Automatic therapeutic interchange
- Restricted antimicrobial agents
 - Approval necessary a priori vs. concurrent review and feedback
- Antibiotic order forms
- Infectious Diseases consultations

Establishing an Antimicrobial Stewardship Program

Multiple guidelines exist in the literature

- IDSA guidelines for developing an institutional program to enhance antimicrobial stewardship Clin Infect Dis 2007;44: 159–177
- Policy statement on antimicrobial stewardship Infect Control Hosp Epidemiol. 2012;33:322-7
- Guidance for the knowledge and skills required for antimicrobial stewardship leaders Infect Control Hosp Epidemiol. 2014 35(12):1444-51
- Implementing an antibiotic stewardship program: IDSA evidence based guideline Clin Infect Dis. 2016 May 15;62(10):1197-202

Components of an Antimicrobial Stewardship Program

Minimum Requirements

- Core multidisciplinary team formation
- Formulary with restrictions
- Guidelines relevant to the facility and preauthorization for certain agents
- Measure and monitor antimicrobial use
- Provision of local antibiograms
- Core and Supplemental Strategies
 - Core: Formulary restrictions and prospective audit and feedback
 - Supplemental: education, pathways, de-escalation, iv to oral stepdown, others

Tailoring or De-Escalating Antimicrobials

- Based on natural history of clinical phases of illness
- Acute \rightarrow Subacute \rightarrow Convalecent phase
- Empiric antibiotics in acute phase
- Entry to subacute phase about 72-96 hours
- Susceptibilities arrive 48-72 hours
- Timing at Day 3 ideal as process measure to tailor or de-escalate

Pulcini C, Defres S, Aggarwa I, Nathwani D, Davey P. Design of a 'day 3 bundle' to improve the reassessment of inpatient empirical antibiotic prescriptions. Journal of Antimicrobial Chemotherapy (2008) 61, 1384–1388 doi:10.1093/jac/dkn113

Clinical Benefits of Sequential Antibiotic Therapy

Earlier discontinuation of IV
Increased patient comfort
Decreased risk of complications
Enhanced mobilization
Reduced risk of nosocomial infection
Earlier discharge from hospital
Improved quality of life

You wouldn't like me when I'm angry...


> Because I always back up my rage with facts and documented sources.

-The Credible Hulk

Evidence Base to Support Antimicrobial Stewardship

Reduction in antimicrobial resistance

- Finland's consumption of macrolide antibiotics decreased from 2.40 defined daily doses/1000 inhabitants/day in 1991 → 1.38/1000 inhabitants/day in 1992 (p=0.007) and continued to 1996 due to national guidelines.
- With decrease in consumption ↓ in erythromycin resistance of Gr. A streptococci from throat swabs – 16.5% (1992) → 8.6% (1996)



Seppala H et al. N Engl J Med 1997;337:441-446

Evidence Base to Support Antimicrobial Stewardship

Current evidence on hospital antimicrobial stewardship objectives: a systematic review and meta-analysis



Emelie C Schuts, Marlies E J L Hulscher, Johan W Mouton, Cees M Verduin, James W T Cohen Stuart, Hans W P M Overdiek, Paul D van der Linden, Stephanie Natsch, Cees M P M Hertogh, Tom F W Wolfs, Jeroen A Schouten, Bart Jan Kullberg, Jan M Prins

Summary

Background Antimicrobial stewardship is advocated to improve the quality of antimicrobial use. We did a systematic review and meta-analysis to assess whether antimicrobial stewardship objectives had any effects in hospitals and long-term care facilities on four predefined patients' outcomes: clinical outcomes, adverse events, costs, and bacterial resistance rates.

Methods We identified 14 stewardship objectives and did a separate systematic search for articles relating to each one in Embase, Ovid MEDLINE, and PubMed. Studies were included if they reported data on any of the four predefined outcomes in patients in whom the specific antimicrobial stewardship objective was assessed and compared the findings in patients in whom the objective was or was not met. We used a random-effects model to calculate relative risk reductions with relative risks and 95% CIs.

Findings We identified 145 unique studies with data on nine stewardship objectives. Overall, the quality of evidence was generally low and heterogeneity between studies was mostly moderate to high. For the objectives empirical therapy according to guidelines, de-escalation of therapy, switch from intravenous to oral treatment, therapeutic drug monitoring, use of a list of restricted antibiotics, and bedside consultation the overall evidence showed significant benefits for one or more of the four outcomes. Guideline-adherent empirical therapy was associated with a relative risk reduction for mortality of 35% (relative risk 0.65, 95% CI 0.54-0.80, p<0.0001) and for de-escalation of 66% (0.44, 0.30-0.66, p<0.0001). Evidence of effects was less clear for adjusting therapy according to renal function, discontinuing therapy based on lack of clinical or microbiological evidence of infection, and having a local antibiotic guide. We found no reports for the remaining five stewardship objectives or for long-term care facilities.

Interpretation Our findings of beneficial effects on outcomes with nine antimicrobial stewardship objectives suggest they can guide stewardship teams in their efforts to improve the quality of antibiotic use in hospitals.

Funding Dutch Working Party on Antibiotic Policy and Netherlands National Institute for Public Health and the Environment.

Lancet Infect Dis 2016

Published Online March 2, 2016 http://dx.doi.org/10.1016/ S147 3-3099(16)00065-7

See Online/Articles http://dx.doi.org/10.1016/ \$1473-3099(16)00099-2

Department of Internal Medicine, Division of Infectious Diseases, Centre for Infection and Immunity Amsterdam (CINIMA), Academic Medical Centre, Amsterdam, Netherlands (EC Schuts BSc, Prof J M Prins MD); Scientific Institute for Quality of Healthcare, Radboud Institute for Health Sciences (Prof M EJ L Hulscher PhD), Department of Pharmacy (S Natsch Pharm D), and Department of Internal Medicine, Centre for Infectious Diseases (Prof B | Kullberg MD), **Radboud University Medical** Centre, Nijmegen, Netherlands; Department of Medical Microbiology and Infectious Diseases, Erasmus MC, Rotterdam, Netherlands (Prof JW Mouton MD); Department of Medical

Effects on Mortality of Stewardship Components

De-escalation (Forest Plot)

Prescribing empiric therapy based on guidelines(Forest plot)

Fig. 1 Effect on mortality of prescribing empirical therapy according to the guideline - CAP

Fig. 2 Effect on mortality of de-escalation of therapy based on culture results

	Experimental Cont			ol	Odds Ratio		Odds Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% CI	
Alvarez-Lerma et al (2006)	7	48	9	36	6.4%	0.51 [0.17, 1.54]		
Bal et al (2014)	4	19	4	8	3.6%	0.27 [0.05, 1.57]		
Berild et al (2006)	18	146	0	20	1.7%	5.90 [0.34, 101.78]		
Cremers et al (2014)	8	126	23	149	8.0%	0.37 [0.16, 0.86]		
Eachempati et al (2009)	26	77	24	57	8.9%	0.70 [0.35, 1.42]		
Elhanan et al (1997)	0	0	0	0		Not estimable		
Garnacho-Montero et al (2014)	45	179	65	180	10.6%	0.59 [0.38, 0.94]		
Giantsou et al (2007)	7	58	37	85	7.8%	0.18 [0.07, 0.44]		
Joffe et al (2008)	55	320	13	92	9.2%	1.26 [0.66, 2.43]		
Khasawneh et al (2014)	2	33	5	27	3.7%	0.28 (0.05, 1.60)		
Khasawneh et al (2014) - 2	1	34	6	31	2.6%	0.13 [0.01, 1.12]		
Knaak et al (2013)	11	73	17	44	7.7%	0.28 [0.12, 0.68]	_	
Kollef et al (2006)	15	88	58	245	9.4%	0.66 [0.35, 1.24]		
Koupetori et al (2014)	0	36	0	93		Not estimable		
Leone et al (2014)	18	59	13	57	8.0%	1.49 (0.65, 3.41)	-++	
Mokart et al (2014)	2	44	15	57	4.4%	0.13 [0.03, 0.62]		
Schlueter et al (2010)	2	77	7	25	4.0%	0.07 [0.01, 0.36]		
Schweizer et al (2011)	0	66	0	56		Not estimable		
Shime et al (2011)	1	79	6	122	2.7%	0.25 [0.03, 2.10]		
Shime et al (2013)	0	28	2	11	1.4%	0.07 [0.00, 1.52]		
fotal (95% CI)		1488		1246	100.0%	0.44 [0.30, 0.66]	•	
Total events	222		304				0.020	
Heterogeneity: Tau ^a = 0.34; Chi ^a	= 38.94, df	= 16 (P	= 0.001)	I*= 59	96			
Fest for overall effect: Z = 3.98 (F			0.0223	2 233			0.001 0.1 1 10 1000 Favours [experimental] Favours [control]	

	Experimental		Contr	Control		Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
Arnold et al (2009)	82	975	121	660	6.8%	0.41 [0.30, 0.55]	
Asadi et al (2013)	231	2506	90	697	7.1%	0.68 [0.53, 0.89]	
Blasi et al (2008)	107	1092	234	1755	7.2%	0.71 [0.55, 0.90]	
Dambrava et al (2009)	20	531	13	111	3.7%	0.30 [0.14, 0.61]	
Dean et al (2006)	0	0	0	0		Not estimable	
Diaz et al (2003)	21	196	12	245	3.6%	2.33 [1.12, 4.86]	
Ewig et al (2000)	10	170	5	62	2.1%	0.71 [0.23, 2.17]	
Ferrer et al (2010)	59	160	49	116	5.3%	0.80 [0.49, 1.30]	
Frei et al (2006)	6	53	6	25	1.8%	0.40 [0.12, 1.41]	
Frei et al (2010)	11	357	19	274	3.5%	0.43 [0.20, 0.91]	
Garcia et al (2007)	49	96	40	69	4.3%	0.76 [0.41, 1.41]	
Grenier et al (2011)	86	1557	109	1097	6.9%	0.53 [0.39, 0.71]	
Huijts et al (2013)	0	947	0	89		Not estimable	
Huvent-Grelle et al (2004)	17	64	11	48	3.0%	1.22 [0.51, 2.91]	
Kett et al (2011)	84	129	137	174	5.1%	0.50 [0.30, 0.84]	
Malone et al (2001)	0	279	0	51		Not estimable	
Marras et al (1998)	24	201	7	51	2.8%	0.85 [0.35, 2.11]	
Marras et al (2004)	34	386	4	32	2.1%	0.68 [0.22, 2.04]	
Maxwell et al (2005)	2	124	23	567	1.4%	0.39 (0.09, 1.67]	
Menendez et al (2002)	24	259	7	36	2.7%	0.42 [0.17, 1.07]	
Menendez et al (2005)	52	960	22	245	5.0%	0.58 [0.35, 0.98]	
Menendez et al (2007)	19	190	11	81	3.3%	0.71 [0.32, 1.56]	
Miletin et al (2001)	8	37	7	38	2.0%	1.22 [0.39, 3.80]	
Mortensen et al (2004)	20	323	21	97	4.1%	0.24 [0.12, 0.46]	
Pradelli et al (2014)	35	847	37	1370	5.4%	1.55 [0.97, 2.49]	
Reves et al (2007)	28	325	9	100	3.3%	0.88 [0.40, 1.94]	
Sakaguchi et al (2013)	4	16	17	69	1.7%	1.02 [0.29, 3.58]	
Silveira et al (2012)	0	66	0	46		Not estimable	
Triantafyllidis et al (2012)	14	152	17	100	3.5%	0.50 [0.23, 1.06]	
Wilke et al (2011)	10	44	7	38	2.2%	1.30 [0.44, 3.84]	
Total (95% CI)		11750		8157	100.0%	0.66 [0.55, 0.79]	•
Total events	1055		1035				C- 20
Heterogeneity: Tau* = 0.11;	Chi ² = 61.	29, df = 3	25 (P < 0	0001);	I ² = 59%		0.01 0,1 10 10
Test for overall effect: $Z = 4$.	37 (P < 0.0	0001)					0.01 0.1 1 10 10 Favours (experimental) Favours (control)

Guideline-adherent empirical therapy RRR for mortality of 35% (relative risk 0.65, 95% CI 0.54–0.80, p<0.0001) and for de-escalation of 56% (0.44, 0.30–0.66, p<0.0001)

Stewardship in ICU-Systematic Review

- Any experimental intervention (any type stewardship) to improve antimicrobial utilization in ICU
- 24 studies met inclusion criteria; 2 de-escalation
 3 RCTs, 3 ITS & 18 uncontrolled before-after studies

Outcomes

- reductions in antimicrobial utilization (11%–38% DDD/1000 pt-days)
- Iower total antimicrobial costs (US \$5–10/patient-day)
- shorter average duration of antibiotic therapy, less inappropriate use and fewer antibiotic adverse events
- stewardship > 6 months associated with \$\geq\$ antimicrobial resistance rates and no change NIs, LOS or mortality

Kaki et al. Impact of antimicrobial stewardship in critical care: a systematic review. Antimicrob Chemother 2011; 66: 1223–1230

De-escalation in ICU

- Cohort study on the safety and impact on in hospital and 90-day mortality of antibiotic de-escalation in patients admitted to the ICU with severe sepsis or shock (n=628)
- De-escalation in 219 patients;
 - By MV analysis, independent RF associated with in-hospital mortality were septic shock, SOFA score the day of culture, inadequate empirical antimicrobial therapy
 - De-escalation was a protective factor [OR 0.58; 95 % CI 0.36–0.93]
- Why? Less toxicity; NI; collateral damage

Garnacho-Montero et al. De-escalation of empirical therapy is associated with lower mortality in patients with severe sepsis and septic shock Intensive Care Med (2014) 40:32– 40

Effectiveness of Antimicrobial Stewardship Policies

 Based on evidence most effective interventions appear to be restrictive administrative methods including formulary control applied at the institution or provincial level

Davey P et al. Cochrane Database Sys Rev 2005;(4):CD003543

Antimicrobial Utilization and Stewardship in the Canadian Setting

Historic issues
Public Health Agency of Canada initiatives
Accreditation Canada
Provincial initiatives

Local Initiatives

Stewardship in the Canadian Setting Historic overview

- 1997 Canadian Consensus Conference "Controlling antimicrobial resistance. An integrated action plan for Canadians" recommendations
 - establish antibiotic stewardship and antibiotic use teams in all Canadian hospitals by:
 - a. using accreditation standards
 - b. obtaining support from administrative leadership
 - establish antimicrobial use, monitoring, and intervention programs
- 2002 National Policy Conference and 2004 National Action Plan Antimicrobial Stewardship Recommendations
 - obtain, analyze and disseminate data/information on antibiotic use in humans and animals

Rennert-May E, Conly J Antimicrobial Stewardship: A Canadian Perspective . 2016. Int J Health Gov

Stewardship in the Canadian Setting Historic overview

- 2009 Pan-Canadian Stakeholder Consultations on Antimicrobial Resistance
 - develop a universally agreed to definition of stewardship
 - develop a coordinated integrated inter-disciplinary Pan-Canadian approach....
 - develop and promote public and professional awareness of antimicrobial stewardship responsibilities and concerns
- 2014 Senate Briefings; NCCID Report of Antimicrobial Resistance and Antimicrobial Utilization in Canada; Accreditation Canada ROP; Federal Framework for Action
 2015 Auditor General Report AMR in Canada

Rennert-May E, Conly J Antimicrobial Stewardship: A Canadian Perspective . 2016. Intern J Health Gov


Available AMU Data Canada

IMS Brogan Products :


- Canadian Drug Store & Hospital Purchases (CDH)
- Canadian CompuScript (CSC)
- Canadian Disease and Therapeutic Index (CDTI)
- Retail Prescription
- First Nations and Inuit Health Branch (FNIHB) Non-insured prescription
- CNISP Hospital-based antimicrobial usage

Metrics for monitoring use


Prescription rates




DDD per prescription



DDD rates



Total kilograms of active ingredient



Courtesy PHAC CNISP Kahina Abdesselam

CNISP AMU 2015-16


- Approximately 40 sites participating (missing quite a few AMU data)
- 3 pediatrics stand alone participating in 2015 but potentially only 2 participating in 2016
- Variables collected:
 - Antimicrobial
 - Total grams administered or the administered daily dose
 - Bed size
 - Patient days
 - Calendar year
 - Route of administration
 - DOT for pediatric sites

Courtesy PHAC CNISP Kahina Abdesselam

Overall Trend

- Antimicrobial consumption has remained stable over the last 5 yrs but 6% decrease in consumption rate
- Significant Individual drug trend over the last 5 years
 - − ↑ 115% Doxycycline
 - − ↑ 107% Ertapenem
 - 个 64% Clavulin
 - $\sqrt{37\%}$ Cefuroxime
 - $-\downarrow$ 28% Clarithromycin
 - $-\downarrow$ 21% Ciprofloxacin
- Antimicrobial consumption based on different categories of bed sizes were not significantly different over the last 5 years
 - > 500 bed size reported 573 DDD per 1,000 patient days; 200 to 500 bed size reported 653 DDD per 1,000 patient days and <200 bed size reported 1,042 DDD per 1,000 patient days

Ten most prescribed antimicrobial by DDD per 1,000 patient-days reported by CNISP participating hospitals between 2009 and 2013 in Canada



Atimicrobial Use Working Group Canadian Noscomial Infection Surveillance Program

Courtesy PHAC CNISP Kahina Abdesselam

Accreditation Canada and Stewardship

Antimicrobial stewardship can accomplish:

- In combination with a comprehensive infection control program has been shown to limit the emergence and transmission of antimicrobial-resistant bacteria.
- Studies also indicate that antimicrobial stewardship programs are cost effective, and provide savings through reduced drug costs and avoidance of microbial resistance

A New Accreditation Standard

- Accreditation Canada developed a "Required Organizational Practice" (ROP) under Medication Use on Antimicrobial Stewardship in 2013
 - The organization has a program for antimicrobial stewardship to optimize antimicrobial use"
 - Applies to all acute care organizations
 - Applicable as of May 2014
 - Organizations should use a tailored approach consistent with their size, service environment and patient population

ROP Tests of Compliance

- 1. The organization implements an antimicrobial stewardship program
- 2. The program includes lines of accountability for implementation
- 3. The program is inter-disciplinary
- 4. The program includes interventions to optimize antimicrobial use that may include:
 - audit and feedback
 - a formulary with approved indications
 - guidelines and clinical pathways for antimicrobial utilization
 - strategies for streamlining or de-escalation of therapy
 - parenteral to oral conversion of antimicrobials
 - education
 - dose optimization

Provincial Initiatives

Ontario

- Public Health Ontario and OHA partnership to focus on stewardship within Ontario hospitals
- Major Consensus Conference planning for stewardship
- Quebec
 - 2011 study from Quebec described the impact of a bundle approach on ambulatory prescribing
- BC
 - Multiple initiatives "Do Bugs Need Drugs", PharmaNet utilization, BC Clinical Care Management program aims to improve stewardship
- Alberta
 - Alberta wide approach via its 5 zones

Alberta Stewardship Initiatives


Theme: "Reduce Your Antibiotic Footprint"

Current:

- Provincial ASC
- Common formulary and TIs and restrictions
- Zone Committees roll up
- Annual AS report

New:

Zone Progress ReportsZone Initiatives Reports



Reviewed Early/Prescribed Surely Day 3 Bundle (D3B) for antimicrobials **Reassess initial diagnosis Review all microbiology results Tailor antimicrobials; choice & duration** Switch intravenous to oral route

Prospective Audit and Feedback Hospitalist Services


Re-organization in Pharmacy allowed 4 ID trained pharmacists to conduct daily reviews all new antibiotic starts FMC hospitalists – rounds discussion or note to chart

 Rotation of ID physicians who provide daily discussion of difficult cases

Evaluation after 1 year revealed 80% acceptance of recommendations (full or partial) and significant improvement de-escalation and conversion to po antibiotics



Get the right drug for the right bug at the right dose and the right duration.




SpectrumCalgary

Spectrum is an adaptable and locally tailored antimicrobial stewardship application

Goals:

- To educate users on antimicrobial stewardship principles and optimal prescribing through the app experience
- To improve the appropriate antimicrobial utilization for common infectious syndromes in hospitalized patients in Calgary
- To expand of the product in scope, location, and media and improve existing content through incorporation of user feedback in an iterative fashion

By Syndrome



Detterrie mitte ODD eterriet

SPECTRUM

(your site/region/city...)

- User friendly (above average usability)
- Iterative open source feedback



- iTunes downloadable free app for Spectrum Calgary
- Menus of options for specific site development
 - Base of antimicrobials/pathogens/antiobiograms
 - Optional customization of algorithms
 - Optional add local epidemiology
- Future: Android version coming and ICU outcomes evaluation completed and submitted IDSA

spectrum.md

The power to make a difference in stewardship is in your hands